Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Trulieve Cannabis (TRLV) Advances +9% Over 30 Days as Federal Policy Evolves

Trulieve Cannabis (TRLV) Advances +9% Over 30 Days as Federal Policy Evolves

Key Takeaways

  • TRLV rose roughly 9% over the trailing 30 days, from about $10.00 in mid-October to a latest close near $10.90, a measured move rather than a sharp momentum swing.
  • Trulieve became the first U.S. cannabis company to list on a major U.S. exchange, debuting on the NYSE under TRLV on June 10, 2026.
  • Third-quarter 2026 results, reported November 5, showed revenue of $230 million, a 64% gross margin, $1 million in net income, and adjusted EBITDA of $89 million (39% of revenue).
  • Adjusted diluted EPS of $0.09 exceeded analyst expectations, while reported revenue declined on a year-over-year basis partly due to the deconsolidation of Harvest operations.
  • Federal rescheduling of state-licensed medical marijuana to Schedule III, together with final DEA registrations, is reshaping the company's tax and operating economics.
  • A seven-fold increase in Georgia traffic following the state's medical program expansion and a pending Texas license anchor the company's growth narrative.
  • For additional data, explore Trulieve's Price Targets, Earnings, and Forecast pages.
  • Discover curated, top-performing strategies on Trending AI Robots.

Market Snapshot

Trulieve Cannabis shares have shown notable volatility since their New York Stock Exchange debut. Over the trailing 30 days, TRLV advanced approximately 9%, recovering from a mid-October close near $10.00 to a latest close around $10.90. The move remains below double-digit territory, keeping the stock in a consolidation phase rather than an extended breakout. Earlier in the period, shares reached above $12.90 in late September before pulling back sharply, and TRLV has since fluctuated largely within a $10 to $11.50 band. The company's market capitalization sits near $2 billion, and its inclusion in the S&P Total Market Index, S&P Completion Index, and Morningstar Total Stock Market Index has broadened its investor base. Sentiment remains closely tied to federal cannabis policy developments and the pace of state-level program expansion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Trulieve Cannabis (TRLV) Business Overview and Competitive Position

Trulieve Cannabis Corp. is a vertically integrated U.S. cannabis operator engaged in cultivation, processing, manufacturing, and retail distribution of medical and adult-use products. Headquartered in Tallahassee, Florida, the company operates 208 retail dispensaries and roughly 3.5 million square feet of cultivation and processing capacity across the United States. Its in-house brands, including Modern Flower, Roll One, and Cultivar, are complemented by partner brands such as Alien Labs and Connected. Trulieve is led by Chief Executive Officer Kim Rivers and holds a leadership position in Florida, one of the nation's largest medical markets. Its status as a Schedule III-registered, NYSE-listed operator distinguishes it from most peers, and its vertically integrated model supports comparatively strong gross margins and cash generation. Investors follow TRLV as a benchmark for how federal rescheduling and state program expansion translate into financial results for a leading multi-state operator.

Recent Developments Driving TRLV

The most significant recent development is the federal rescheduling of state-licensed medical marijuana to Schedule III under the Controlled Substances Act, following which Trulieve received final DEA registrations for its medical operations. The company has described the change as removing barriers to research, reducing stigma, and enabling a more level playing field for lawful operators. On the financial side, third-quarter results showed a 64% gross margin, positive net income of approximately $1 million, and adjusted EBITDA of $89 million, reflecting disciplined promotional activity and operational efficiency. Cash flow from operations reached $74 million in the quarter, with $45 million in free cash flow, supporting a quarter-end cash balance of $327 million. Trulieve also repaid a $65 million mortgage ahead of its 2028 maturity to reduce leverage and interest expense. Operationally, the company reported a seven-fold increase in Georgia traffic and units following the state's July 1 medical program expansion, began shipping branded products to nearly 20 independent pharmacies, and closed a perpetual royalty-free license for Alien Labs and Connected products in Florida and Texas. It also completed its corporate domestication to Delaware and was added to several major equity indexes.

2026 Outlook and What Investors Should Watch

Trulieve's forward trajectory depends heavily on the completion of broader federal rescheduling of marijuana to Schedule III, which could remove the punitive Section 280E tax burden and unlock additional cash flow. Management has indicated it expects Treasury guidance on tax treatment, including potential retroactive relief, following the rescheduling process. Investors should also monitor Texas, where Trulieve holds a conditional license and has said final approval is anticipated as soon as 2026; initial production capacity is prepared for inspection. In Georgia, continued patient growth and pharmacy distribution represent near-term expansion levers, while Florida remains the core market and any shift toward adult-use legalization would carry both opportunity and competitive risk. Key risks include price compression, state-level regulatory uncertainty, and execution in new markets. For the fourth quarter, the company has guided for revenue up low single digits sequentially, while noting a net loss is expected due to purchase accounting adjustments tied to the Harvest deconsolidation. From what I see, this remains a key area to track closely.

Exploring AI Tools for Trading Insights

I often review Tickeron’s Trending AI Robots page to identify top-performing strategies across various timeframes and objectives. The curated list highlights bots with strong track records, making it easier to compare approaches and align them with specific portfolio goals without sifting through hundreds of options. This resource has become a practical part of my routine when evaluating names like TRLV alongside other equities.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TRLV

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


TRLV in downward trend: price dove below 50-day moving average on November 12, 2026

TRLV moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 39 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 49 cases where TRLV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

TRLV broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TRLV as a result. In 61 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for TRLV just turned positive on October 22, 2026. Looking at past instances where TRLV's MACD turned positive, the stock continued to rise in 25 of 33 cases over the following month. The odds of a continued upward trend are 76%.

The 10-day moving average for TRLV crossed bullishly above the 50-day moving average on November 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +2.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in 186 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 129 of 157 cases where TRLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.901) is normal, around the industry mean (6.379). P/E Ratio (-4.680) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 7%. AKAN experienced the highest price growth at 62%, while GLAS experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 9%. For the same stocks of the Industry, the average monthly volume growth was 15% and the average quarterly volume growth was 2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 55
Price Growth Rating: 60
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 9 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
3494 Martin Hurst Road
Phone
+1 850 298-8866
Employees
5000
Web
https://www.trulieve.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
Alphabet (GOOGL) fell roughly 15.3% over the last 30 days, sliding from about $349.22 to $295.77, driven primarily by a post-earnings selloff. The decline followed Alphabet's Q3 2026 results, when earnings per share of $2.12 badly missed the $3.02 consensus estimate.
CRM pairs an AI-driven growth story (notably its Agentforce platform) against rising leverage, acquisition spending, and a recent S&P credit-rating downgrade, keeping shares below key moving averages. INTU has rebounded sharply off its 52-week low on renewed analyst support and an AI workflow-automation narrative, even though it remains far below its prior high.